EMA and HTA bodies jointly review a proposed EU framework for patient preference studies
By EsqSocial Corporation 02/11/20
The European Medicines Agency (“EMA”) and the EU network of Health Technology Assessment (“HTA”) bodies are jointly reviewing a proposed framework for patient preference studies. The intention of the proposed framework is to provide recommendations to support the development of guidelines concerning the inclusion of patient preferences on the benefit-risk assessment of medicinal products and medical devices....
By: Hogan Lovells